Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.557 Ladies and gentlemen, thank you for standing by and welcome to Niagen Bioscience Inc.' 00:00:04.557 -- 00:00:08.122 's first quarter 2026 earnings conference call. 00:00:08.122 -- 00:00:10.966 My name is Karina and I will be the conference operator today. 00:00:10.966 -- 00:00:15.552 At this time, all participants are in a listen-only mode. 00:00:15.552 -- 00:00:18.977 As a reminder, this conference call is being recorded. 00:00:18.977 -- 00:00:24.605 Earlier today, Niagen Bioscience issued a press release announcing its financial results 00:00:24.605 -- 00:00:29.512 for the first quarter of 2026. If you have not reviewed this information... 00:00:29.512 -- 00:00:35.022 It is available within the Investor Relations section of Niogen Bioscience's website 00:00:35.022 -- 00:00:37.683 at www.niogenbioscience.com. 00:00:39.249 -- 00:00:43.817 I would now like to turn the call over to Lauren Brzozanski, Assistant Controller. 00:00:43.817 -- 00:00:45.620 Please go ahead. 00:00:45.620 -- 00:00:50.588 Good afternoon, and welcome to Niogen Bioscience, Inc.' 's first quarter 2026 conference 00:00:50.588 -- 00:00:55.660 call. Joining me today are our Chief Executive Officer, Rob Freed, 00:00:55.660 -- 00:01:00.847 Chief Financial Officer, Ozan Pamir, and Senior Vice President of Scientific and Regulatory 00:01:00.847 -- 00:01:07.033 Affairs, Dr. Andrew Hsiao. Dr. Hsiao will be joining the call for Q&A. 00:01:07.877 -- 00:01:12.122 Before we begin, I'd like to remind everyone that today's call may include forward-looking 00:01:12.122 -- 00:01:16.883 statements. These statements relate to, among other things, our research and development 00:01:16.883 -- 00:01:21.909 activities, clinical trial plans and timing, regulatory filings, expansion 00:0...